恶性胸膜间皮瘤的晚期和复发性免疫治疗。
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.
机构信息
Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
Digestive Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
出版信息
Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of immune checkpoint inhibitors (single-agent or combination therapy) in people with advanced malignant pleural mesothelioma in a first-line or salvage setting.
摘要
这是一篇 Cochrane 综述（干预措施）的方案。其目的如下：评估免疫检查点抑制剂（单药或联合治疗）在一线或挽救治疗中晚期恶性胸膜间皮瘤患者中的疗效。
相似文献
1
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.
Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.
2
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5. doi: 10.1080/14737140.2016.1191951. Epub 2016 May 30.
3
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.
4
First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
Lung Cancer. 2024 Aug;194:107891. doi: 10.1016/j.lungcan.2024.107891. Epub 2024 Jul 14.
5
Is there a role for immunotherapy in malignant pleural mesothelioma?
Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x.
6
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Am J Respir Cell Mol Biol. 2014 May;50(5):870-5. doi: 10.1165/rcmb.2013-0472TR.
7
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024.
8
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.
Future Oncol. 2015;11(24 Suppl):23-7. doi: 10.2217/fon.15.312.
9
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
10
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Clin Respir J. 2019 May;13(5):272-279. doi: 10.1111/crj.13010. Epub 2019 Mar 24.
引用本文的文献
1
Pleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.
Transl Lung Cancer Res. 2025 Jul 31;14(7):2611-2625. doi: 10.21037/tlcr-2025-198. Epub 2025 Jul 28.
本文引用的文献
1
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
Lancet Respir Med. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10.
2
ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis.
BMJ. 2023 Nov 20;383:e076754. doi: 10.1136/bmj-2023-076754.
3
Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades.
SSM Popul Health. 2023 Jun 3;23:101441. doi: 10.1016/j.ssmph.2023.101441. eCollection 2023 Sep.
4
Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017.
JAMA Netw Open. 2021 Aug 2;4(8):e2120360. doi: 10.1001/jamanetworkopen.2021.20360.
5
Controversies in the role of radiotherapy in pleural mesothelioma.
Transl Lung Cancer Res. 2021 Apr;10(4):2079-2087. doi: 10.21037/tlcr-20-583.
6
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
9
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
10
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.
Ther Adv Med Oncol. 2020 Nov 12;12:1758835920971421. doi: 10.1177/1758835920971421. eCollection 2020.
Zotero 插件